Altamira Therapeutics Stock Price, News & Analysis (NASDAQ:CYTO) $0.44 +0.08 (+20.88%) (As of 09:04 AM ET) Add Compare Share Share Today's Range$0.44▼$0.4450-Day Range$0.10▼$0.6452-Week Range$0.09▼$5.99Volume4.86 million shsAverage Volume4.48 million shsMarket Capitalization$3.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About Altamira Therapeutics Stock (NASDAQ:CYTO)Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.Read More CYTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTO Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 5, 2023 | benzinga.comThinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?November 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNovember 20, 2023 | uk.finance.yahoo.comTrending tickers: Microsoft | Bitcoin | Altamira | AshteadNovember 17, 2023 | msn.comAltamira stock surges after deal to sell 51% stake in MedicaNovember 17, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 160% Today?December 6, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 17, 2023 | marketwatch.comAltamira Therapeutics Shares Surge on Sale of Bentrio UnitNovember 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNovember 10, 2023 | finance.yahoo.comAltamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNovember 3, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 28% Today?September 14, 2023 | marketwatch.comAltamira Therapeutics Shares Rise on Positive Bentrio Trial ResultsSeptember 14, 2023 | finance.yahoo.comAltamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisSeptember 13, 2023 | insidermonkey.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call TranscriptSeptember 12, 2023 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 12, 2023 | finance.yahoo.comAltamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 8, 2023 | markets.businessinsider.comAltamira Therapeutics Ltd Registered Shs hosts conference call for investorsSeptember 6, 2023 | finance.yahoo.comAltamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thAugust 23, 2023 | uk.finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 23, 2023 | finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13July 20, 2023 | finance.yahoo.comAltamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaJuly 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalJuly 6, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Getting HammeredJuly 6, 2023 | finance.yahoo.comAltamira Therapeutics Announces Pricing of $5.0 Million Public OfferingJuly 5, 2023 | finance.yahoo.comAltamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationSee More Headlines Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.27 Sales & Book Value Annual Sales$120,287.00 Price / Sales21.03 Cash FlowN/A Price / Cash FlowN/A Book Value($7.38) per share Price / Book-0.05Miscellaneous Outstanding Shares6,989,000Free Float6,078,000Market Cap$2.53 million OptionableNot Optionable Beta1.69 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Thomas Meyer Ph.D. (Age 55)Founder, Chairman, CEO & MD Comp: $566.88kMr. Marcel Gremaud CPA (Age 65)Chief Financial Officer Dr. Covadonga Paneda (Age 49)Chief Operating Officer Dr. Samuel A. Wickline M.D. (Age 70)Chief Scientific Adviser Key CompetitorsInMed PharmaceuticalsNASDAQ:INMCohBarNASDAQ:CWBRComera Life SciencesNASDAQ:CMRAScopus BioPharmaNASDAQ:SCPSAvenue TherapeuticsNASDAQ:ATXIView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 829,000 shares on 11/15/2023Ownership: 11.860%View All Institutional Transactions CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed in 2023? Altamira Therapeutics' stock was trading at $4.85 at the beginning of 2023. Since then, CYTO stock has decreased by 92.5% and is now trading at $0.3620. View the best growth stocks for 2023 here. Are investors shorting Altamira Therapeutics? Altamira Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average daily trading volume, of 8,950,000 shares, the days-to-cover ratio is presently 0.1 days. View Altamira Therapeutics' Short Interest. When did Altamira Therapeutics' stock split? Altamira Therapeutics shares reverse split before market open on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CYTO) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.